471 related articles for article (PubMed ID: 21692551)
21. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
Hiligsmann M; Maggi S; Veronese N; Sartori L; Reginster JY
Osteoporos Int; 2021 Mar; 32(3):595-606. PubMed ID: 33443610
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
23. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France.
Cotté FE; De Pouvourville G
BMC Health Serv Res; 2011 Jun; 11():151. PubMed ID: 21702989
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
25. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
26. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.
Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
Osteoporos Int; 2005 Dec; 16(12):1883-93. PubMed ID: 16133649
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Tian L; Luo C; Li YF; Wang QY; Qu XL; Yue C; Xu LL; Yang YY; Sheng ZF
Arch Osteoporos; 2023 Jul; 18(1):100. PubMed ID: 37460858
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia.
Choo YW; Mohd Tahir NA; Mohamed Said MS; Li SC; Makmor Bakry M
Osteoporos Int; 2022 Sep; 33(9):1909-1923. PubMed ID: 35641572
[TBL] [Abstract][Full Text] [Related]
31. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
32. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.
Morizio P; Burkhart JI; Ozawa S
Ann Pharmacother; 2018 Oct; 52(10):1031-1041. PubMed ID: 29616561
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
Osteoporos Int; 2010 Mar; 21(3):495-505. PubMed ID: 19565175
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
35. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
[TBL] [Abstract][Full Text] [Related]
36. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
39. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
